Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Universe PharmaceuticalsUPC -2.15%62 Earnings Yield (Joel Greenblatt) % is 15.65% as of Sep. 2025, which is 4% below its 10-year median of 16.34. GuruFocus rates UPC with a GF Score™ of 62/100 and a GF Value™ of $5.16 (Modestly Undervalued). The stock has 7 warning signs investors should review. Among 1,011 Drug Manufacturers companies, Universe Pharmaceuticals ranks worse than 98911.87% on this metric.
Universe Pharmaceuticals's Enterprise Value for the quarter that ended in Sep. 2025 was $-21.97 Mil.
Universe Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Sep. 2025 was $-3.44 Mil. Universe Pharmaceuticals's Earnings Yield (Joel Greenblatt) for the quarter that ended in Sep. 2025 was 15.65%.
The historical rank and industry rank for Universe Pharmaceuticals's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
UPC'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -99999999.99 Med: 16.34 Max: 2595.11
Current: 15.87
During the past 8 years, the highest Earnings Yield (Joel Greenblatt) of Universe Pharmaceuticals was 2595.11%. The lowest was -99999999.99%. And the median was 16.34%.
UPC's Earnings Yield (Joel Greenblatt) % is not ranked
in the Drug Manufacturers industry.
Industry Median: 3.3
vs UPC: 15.87
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Universe Pharmaceuticals's Forward Rate of Return (Yacktman) % for the quarter that ended in Sep. 2025 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
Universe Pharmaceuticals Earnings Yield (Joel Greenblatt) % Related Terms
Universe Pharmaceuticals Earnings Yield (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Universe Pharmaceuticals's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Universe Pharmaceuticals's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Universe Pharmaceuticals Earnings Yield (Joel Greenblatt) % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Universe Pharmaceuticals's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Universe Pharmaceuticals's Earnings Yield (Joel Greenblatt) % falls into.
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
Universe Pharmaceuticalss Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Sep. 2025 is calculated as
For company reported semi-annually or annually, GuruFocus only calculate annual data for Earnings Yield (Joel Greenblatt) and apply the annual figure to corresponding quarter.
What does a Earnings Yield (Joel Greenblatt) % of 15.65% mean?
Universe Pharmaceuticals (UPC) has a Earnings Yield (Joel Greenblatt) % of 15.65% as of Sep. 2025. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Universe Pharmaceuticals and its competitors. This is near median its historical median of 16.34. According to the industry distribution chart, Universe Pharmaceuticals ranks #999999 out of 1011 companies in the Drug Manufacturers industry.
Is Universe Pharmaceuticals' Earnings Yield (Joel Greenblatt) % too high?
Universe Pharmaceuticals' current Earnings Yield (Joel Greenblatt) % of 15.65% is near median its 10-year median of 16.34. The Drug Manufacturers industry median Earnings Yield (Joel Greenblatt) % is 3.30. Universe Pharmaceuticals' value of 15.65% is 374.2% above this industry median. Based on the distribution chart, Universe Pharmaceuticals ranks #999999 out of 1011 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Universe Pharmaceuticals has a GF Score™ of 62/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Universe Pharmaceuticals' Earnings Yield (Joel Greenblatt) % compare to CPMD and SHPH?
According to the Drug Manufacturers industry distribution chart, Universe Pharmaceuticals ranks #999999 out of 1011 companies for Earnings Yield (Joel Greenblatt) %. This places Universe Pharmaceuticals in the lower half of its industry. The industry median Earnings Yield (Joel Greenblatt) % is 3.30. Universe Pharmaceuticals' value of 15.65% is 374.2% above this benchmark. While the company's 10-year median is 16.34 vs. the industry median of 3.30, Universe Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Yield (Joel Greenblatt) % for a Drug Manufacturers company?
The median Earnings Yield (Joel Greenblatt) % among Drug Manufacturers companies is 3.30, based on 1,011 companies in the industry. Companies in the top quartile (top 25%) have a Earnings Yield (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, Earnings Yield (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Universe Pharmaceuticals's current Earnings Yield (Joel Greenblatt) % of 15.65% is 374.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Yield (Joel Greenblatt) % mean?
A high Earnings Yield (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Universe Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Earnings Yield (Joel Greenblatt) % is 3.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Universe Pharmaceuticals's current Earnings Yield (Joel Greenblatt) % is 15.65%, which is near median its own 10-year median of 16.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Universe Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Universe Pharmaceuticals (UPC) is currently considered Modestly Undervalued. The stock's GF Value™ is $5.16, compared to a current price of $4.09 — trading 20.7% below its estimated fair value. The current Earnings Yield (Joel Greenblatt) % is 15.65%, which is near median its 10-year median of 16.34 and 374.2% above the Drug Manufacturers industry median of 3.30. Universe Pharmaceuticals' overall GF Score™ is 62/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Yield (Joel Greenblatt) % calculated?
Earnings Yield (Joel Greenblatt) % is calculated from a company's financial statements. For Universe Pharmaceuticals (UPC), the current Earnings Yield (Joel Greenblatt) % is 15.65% as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Universe Pharmaceuticals (UPC) Overvalued in 2026?
Based on GuruFocus' analysis, Universe Pharmaceuticals stock appears to be undervalued.
The current stock price of $4.09 is trading 20.7% below its estimated GF Value™ of $5.16.
GuruFocus considers Universe Pharmaceuticals to be Modestly Undervalued.
Key valuation signals for UPC:
Earnings Yield (Joel Greenblatt) %: 15.65% (near median its 10-year median of 16.34)
GF Value™: $5.16 vs. price of $4.09 (20.7% below fair value)
Industry Position: 374.2% above the Drug Manufacturers median (#999999 of 1011)
No single metric tells the full story. See the UPC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Universe Pharmaceuticals Inc is a pharmaceutical company specializing in the manufacturing, marketing, sales and distribution of traditional Chinese medicine derivatives products targeting the elderly with the goal of addressing their physical conditions in the ageing process and promoting their general well-being. The company also sells biomedical drugs, medical instruments, Traditional Chinese Medicine Pieces, and dietary supplements manufactured by third-party pharmaceutical companies. Its products are under two categories namely treatment and relief for common chronic health conditions in the elderly designed to achieve physical wellness and longevity (Chronic Condition Treatments), and cold and flu medications.
62GF Score
Get the complete analysis for UPC
Earnings Yield (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
UPC has been successfully added to your 
